Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.85 HKD | 0.00% | +4.52% | -48.47% |
Apr. 30 | Transcenta Holding Limited Announces Board and Nomination Changes | CI |
Apr. 09 | Transcenta Partners with Agilent to Develop Claudin18.2 Companion Diagnostic | MT |
Strengths
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the past twelve months, EPS forecast has been revised upwards.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- With an enterprise value anticipated at 6.03 times the sales for the current fiscal year, the company turns out to be overvalued.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-48.47% | 96.31M | - | ||
+37.89% | 705B | C+ | ||
+32.82% | 583B | B | ||
-3.62% | 364B | C+ | ||
+20.59% | 332B | B- | ||
+5.60% | 291B | C+ | ||
+16.64% | 238B | B+ | ||
-4.13% | 210B | A+ | ||
+10.63% | 209B | B- | ||
+8.53% | 169B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 6628 Stock
- Ratings Transcenta Holding Limited